Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with and without heart failure at baseline from the EMPA-REG OUTCOME trial.
Event:
Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic:
Miscellaneous
Session:
Late Breaking Trials II: Focus on chronic heart failure